World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
89
Citations
26229
World Ranking
12783
National Ranking
487

Alberto Bosi publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Alberto Bosi sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 585 publications — 70th percentile

70% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Alberto Bosi D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Alberto Bosi sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 89 D-Index — 38th percentile

38% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Alberto Bosi is affiliated with the University of Florence in Italy and has authored numerous publications primarily in the field of Medicine, with a focus on hematology and related disciplines. Their research encompasses key areas such as hematology, genetics, oncology, molecular biology, and pathology and forensic medicine.

Their main topics of study include:

  • Acute Myeloid Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Multiple Myeloma Research and Treatments
  • Chronic Lymphocytic Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Protein Degradation and Inhibitors

Alberto Bosi has published research in several frequently appearing scientific venues such as:

  • European Journal Of Haematology
  • Blood
  • Leukemia
  • Cancers
  • American Journal of Hematology

Some recent papers attributed to the scientific community around this field include:

  • "Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study" (2020), Leukemia
  • "Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study" (2020), Leukemia
  • "Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study" (2020), The Lancet Haematology
  • "Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk" (2020), Journal of Hematology & Oncology
  • "One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab" (2020), European Journal Of Haematology

Frequent co-authors collaborating with Alberto Bosi include:

  • Francesco Mannelli
  • Giacomo Gianfaldoni
  • Benedetta Puccini
  • Monica Bocchia
  • Alessandro M. Vannucchi

Best Publications

  • Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia

    Vanderson Rocha;Myriam Labopin;Guillermo Sanz;William Arcese

  • Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.

    Alessandro M. Vannucchi;Elisabetta Antonioli;Paola Guglielmelli;Alessandro Rambaldi

  • Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO)

    Andrea Bacigalupo;Teresa Lamparelli;Paolo Bruzzi;Stefano Guidi

  • Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

    H Miles Prince;H Miles Prince;Youn H Kim;Steven M Horwitz;Reinhard Dummer

  • Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

    Renato Bassan;Orietta Spinelli;Elena Oldani;Tamara Intermesoli

  • Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party.

    Enric Carreras;Hartmut Bertz;William Arcese;Jean-Paul Vernant

  • Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia

    Giada Rotunno;Carmela Mannarelli;Paola Guglielmelli;Annalisa Pacilli

  • Prospective identification of high-risk polycythemia vera patients based on JAK2 V617F allele burden

    Alessandro Maria Vannucchi;Elisabetta Antonioli;Paola Guglielmelli;G. Longo

  • Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.

    Andrea Bacigalupo;Teresa Lamparelli;Giovanni Barisione;Paolo Bruzzi

  • Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

    Francesco Lo-Coco;Giuseppe Avvisati;Marco Vignetti;Massimo Breccia

  • Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.

    P Ljungman;P Ribaud;M Eyrich;S Matthes-Martin

  • The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease

    Andrea Gallamini;Luigi Rigacci;Francesco Merli;Luca Nassi

  • The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.

    Paola Guglielmelli;Terra L. Lasho;Giada Rotunno;Joannah Score

  • Clinical implications of the JAK2 V617F mutation in essential thrombocythemia

    E Antonioli;P Guglielmelli;A Pancrazzi;C Bogani

  • Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone : a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation

    M T Van Lint;C Uderzo;A Locasciulli;I Majolino

  • Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia.

    Alessandro M. Vannucchi;Elisabetta Antonioli;Paola Guglielmelli;Alessandro Pancrazzi

  • EZH2 mutational status predicts poor survival in myelofibrosis

    Paola Guglielmelli;Flavia Biamonte;Joannah Score;Joannah Score;Claire Hidalgo-Curtis;Claire Hidalgo-Curtis

  • Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.

    Paola Guglielmelli;Giovanni Barosi;Giorgina Specchia;Alessandro Rambaldi

  • Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.

    Andrew Spencer;Suzanne Lentzsch;Katja Weisel;Hervé Avet-Loiseau

  • WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: A study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)

    Emilio Paolo Alessandrino;Matteo Giovanni Della Porta;Andrea Bacigalupo;Maria Teresa Van Lint

Frequent Co-Authors

Alessandro M. Vannucchi
Alessandro M. Vannucchi University of Florence
Alessandro Rambaldi
Alessandro Rambaldi University of Milan
Paola Guglielmelli
Paola Guglielmelli University of Florence
Paolo Corradini
Paolo Corradini University of Milan
Andrea Bacigalupo
Andrea Bacigalupo Catholic University of the Sacred Heart
Fabio Ciceri
Fabio Ciceri Vita-Salute San Raffaele University
Tiziano Barbui
Tiziano Barbui FROM-Fondazione per la Ricerca Ospedale di Bergamo
Giovanni Barosi
Giovanni Barosi University of Pavia
Giorgina Specchia
Giorgina Specchia University of Bari Aldo Moro
Myriam Labopin
Myriam Labopin Université Paris Cité

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in Medicine goes beyond traditional medical school pathways. A variety of online degree options make it possible for students and professionals to enter or advance within the healthcare industry from anywhere.

Those interested in the management side of healthcare can pursue healthcare administration programs. These degrees prepare graduates for leadership roles in hospitals, clinics, and public health organizations.

Registered Nurses aiming to become Family Nurse Practitioners may consider specialized rn to fnp bridge programs. These online programs help nurses expand their clinical scope without putting their careers on hold.

There is also strong demand for experts in nutrition, with flexible online nutrition degree programs available for students interested in dietetics, wellness, or public health nutrition.

For those aspiring to executive-level positions, online mha programs provide accredited pathways to versatile and influential careers leading major healthcare institutions.

Best Scientists Citing Alberto Bosi

Trending Scientists

Recently Published Articles